1St Source Bank decreased Intel Corp (INTC) stake by 6.03% reported in 2018Q4 SEC filing. 1St Source Bank sold 9,532 shares as Intel Corp (INTC)’s stock rose 10.40%. The 1St Source Bank holds 148,675 shares with $6.98M value, down from 158,207 last quarter. Intel Corp now has $244.46 billion valuation. The stock decreased 0.28% or $0.15 during the last trading session, reaching $54.36. About 88,608 shares traded. Intel Corporation (NASDAQ:INTC) has risen 12.75% since April 3, 2018 and is uptrending. It has outperformed by 8.38% the S&P500. Some Historical INTC News: 17/04/2018 – Portland Bus Jrn: Intel unveils new threat security technology; 20/03/2018 – O’Reilly and Intel Announce Lineup for Artificial Intelligence Conference, New York 2018; 12/04/2018 – Sixgill, LLC Named to Intel® IoT Solutions Alliance; 09/05/2018 – Alphabet, Intel, FedEx, AT&T among drone pilot winners -universities; 31/05/2018 – EQS-News: Mobile TeleSystems PJSC: MTS, ERICSSON AND INTEL TESTED A CYBERSPORT VR GAME ON A 5G NETWORK; 08/05/2018 – INTEL CAPITAL REPORTS OVER $70M NEW INVESTMENTS IN 12 STARTUPS; 17/05/2018 – Arias Intel’s SportXction® to Take Advantage of Huge Opportunity After Supreme Court Ruling to Allow States to Legalize Spor; 03/04/2018 – Supermicro First-to-Market with IoT Embedded Solutions optimized for New 8th Gen Intel® Core™ Processors; 19/03/2018 – Intel Votes to Extends Chairman’s Term, Selects New Director; 09/03/2018 – Techmeme: Sources: Intel is working with advisors to consider responses to Broadcom’s Qualcomm bid, including making an
Among 4 analysts covering Biocryst Pharmaceuticals (NASDAQ:BCRX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Biocryst Pharmaceuticals had 5 analyst reports since November 16, 2018 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Tuesday, February 26. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Overweight” rating by PiperJaffray on Friday, November 16. The firm has “Equal-Weight” rating by Barclays Capital given on Tuesday, April 2. The firm has “Market Outperform” rating by JMP Securities given on Tuesday, April 2. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 5. See BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) latest ratings:
02/04/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $6 New Target: $8 Maintain
02/04/2019 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $16 New Target: $18 Maintain
05/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $13 Maintain
26/02/2019 Broker: H.C. Wainwright Rating: Buy New Target: $13 Maintain
16/11/2018 Broker: PiperJaffray Rating: Overweight New Target: $15 Maintain
More notable recent BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news were published by: Globenewswire.com which released: “BioCryst to Present at Upcoming Investor Conferences – GlobeNewswire” on April 01, 2019, also Globenewswire.com with their article: “BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results – GlobeNewswire” published on March 04, 2019, Seekingalpha.com published: “BioCryst Pharma top line down 31% – Seeking Alpha” on March 04, 2019. More interesting news about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were released by: Seekingalpha.com and their article: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on March 04, 2019 as well as Benzinga.com‘s news article titled: “10 Biggest Price Target Changes For Tuesday – Benzinga” with publication date: April 02, 2019.
The stock increased 3.84% or $0.32 during the last trading session, reaching $8.65. About 898,318 shares traded or 23.37% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 79.02% since April 3, 2018 and is uptrending. It has outperformed by 74.65% the S&P500. Some Historical BCRX News: 10/04/2018 – BIOCRYST & IDERA: SPECIAL MEETINGS TO BE HELD ON JULY 10; 01/05/2018 – BioCryst Receives European Medicines Agency Approval for ALPIVAB for the Treatment of Influenza; 29/05/2018 – BIOCRYST ANNOUNCES PRESENTATION OF ADDITIONAL ANALYSES OF THE APEX-1 CLINICAL TRIAL OF BCX7353 AT THE 2018 EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) CONGRESS; 10/04/2018 – BioCryst and Idera Special Meetings to Be Held on July 10; 10/04/2018 – IDERA PHARMACEUTICALS INC – IDERA BOARD UNANIMOUSLY RECOMMENDS THAT IDERA STOCKHOLDERS VOTE “FOR” PROPOSED MERGER AT IDERA SPECIAL MEETING; 02/04/2018 – RA Capital Management, LLC, Affiliates Report Stake In BioCryst Pharmaceuticals; 02/04/2018 – ldera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals; 02/04/2018 – RA CAPITAL SAYS HAS “SERIOUS CONCERNS” ABOUT BIOCRYST PHARMACEUTICALS’ PROPOSED DEAL WITH IDERA AND ITS “DILUTIVE IMPACT” ON BIOCRYST SHAREHOLDERS; 08/05/2018 – BioCryst Pharmaceuticals 1Q Loss/Shr 26c; 08/03/2018 – BioCryst Forms Golden Cross: Technicals
Since October 19, 2018, it had 1 insider purchase, and 23 selling transactions for $2.36 million activity. Shares for $1,720 were sold by STAAB THOMAS R II on Monday, November 5. Barnes Alane P also sold $401,710 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares. 2,000 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares with value of $18,800 were sold by Powell Lynne. ASELAGE STEVE bought 2,000 shares worth $16,600. 80,000 shares were sold by Stonehouse Jon P, worth $729,600 on Monday, December 3. On Tuesday, December 18 Sheridan William P sold $155,299 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 20,488 shares.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $953.03 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.
Investors sentiment decreased to 1.27 in Q4 2018. Its down 0.34, from 1.61 in 2018Q3. It dived, as 11 investors sold BioCryst Pharmaceuticals, Inc. shares while 30 reduced holdings. 27 funds opened positions while 25 raised stakes. 94.16 million shares or 1.13% more from 93.10 million shares in 2018Q3 were reported. Comerica Bankshares invested in 0% or 16,959 shares. Fmr Llc reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Switzerland-based Credit Suisse Ag has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Parametric Ltd Company has 116,110 shares for 0% of their portfolio. Raymond James Service accumulated 28,703 shares. Janney Montgomery Scott Limited Liability Com holds 0% or 27,135 shares. Warren Averett Asset Management Limited Company holds 0.03% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 22,429 shares. Swiss Bank stated it has 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Rhumbline Advisers reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). California Employees Retirement owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 148,673 shares. California State Teachers Retirement Systems stated it has 178,440 shares. Hudson Bay Cap Ltd Partnership has 130,000 shares. Baker Bros Advsrs Limited Partnership holds 1% or 15.10M shares in its portfolio. Tiaa Cref Management Ltd Company has 508,508 shares for 0% of their portfolio. Legal And General Gru Public Ltd Co reported 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Since October 25, 2018, it had 2 buys, and 9 sales for $893,356 activity. $245,993 worth of Intel Corporation (NASDAQ:INTC) was bought by SWAN ROBERT HOLMES on Thursday, December 6. $102,050 worth of stock was sold by Rodgers Steven Ralph on Thursday, October 25. 6,500 shares were sold by McBride Kevin Thomas, worth $295,945. Another trade for 710 shares valued at $33,256 was made by Shenoy Navin on Monday, January 28.
Among 7 analysts covering Intel (NASDAQ:INTC), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Intel had 14 analyst reports since October 22, 2018 according to SRatingsIntel. The company was maintained on Friday, March 15 by Northland Capital. The stock has “Buy” rating by Deutsche Bank on Tuesday, February 26. The firm has “Equal-Weight” rating given on Wednesday, December 19 by Morgan Stanley. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, October 26 report. The firm has “Hold” rating by DZ Bank given on Thursday, November 29. The firm has “Buy” rating given on Friday, January 4 by Bank of America. The firm has “Neutral” rating by Susquehanna given on Friday, January 25. The firm has “Buy” rating by Nomura given on Monday, October 22. The firm earned “Sell” rating on Monday, February 25 by Northland Capital. Citigroup maintained Intel Corporation (NASDAQ:INTC) rating on Tuesday, February 19. Citigroup has “Hold” rating and $50 target.
Analysts await Intel Corporation (NASDAQ:INTC) to report earnings on April, 25. They expect $0.87 EPS, 0.00% or $0.00 from last year’s $0.87 per share. INTC’s profit will be $3.91 billion for 15.62 P/E if the $0.87 EPS becomes a reality. After $1.28 actual EPS reported by Intel Corporation for the previous quarter, Wall Street now forecasts -32.03% negative EPS growth.
Investors sentiment increased to 1 in Q4 2018. Its up 0.15, from 0.85 in 2018Q3. It is positive, as 52 investors sold INTC shares while 677 reduced holdings. 141 funds opened positions while 588 raised stakes. 2.96 billion shares or 3.57% more from 2.86 billion shares in 2018Q3 were reported. Moreover, Baker Ellis Asset Management Lc has 0.33% invested in Intel Corporation (NASDAQ:INTC) for 22,835 shares. Nordea Inv Ab holds 0.93% or 7.15 million shares. First Natl Bank holds 43,271 shares. Delphi Ma holds 43,886 shares or 1.87% of its portfolio. Moreover, Shine Inv Advisory Services has 0.06% invested in Intel Corporation (NASDAQ:INTC) for 2,390 shares. State Street Corporation stated it has 0.82% in Intel Corporation (NASDAQ:INTC). Commonwealth Comml Bank Of Aus stated it has 0.52% in Intel Corporation (NASDAQ:INTC). Factory Mutual Insur stated it has 683,500 shares or 0.41% of all its holdings. Noesis Mangement Corporation invested 0.13% in Intel Corporation (NASDAQ:INTC). Ruggie Grp accumulated 1,440 shares. Windward Mgmt Ca has invested 0.35% in Intel Corporation (NASDAQ:INTC). 9,186 were accumulated by Alphaone Inv Services Limited Liability. Welch And Forbes Ltd Liability holds 1.18% or 892,932 shares. New York-based Neville Rodie And Shaw has invested 1.5% in Intel Corporation (NASDAQ:INTC). Spectrum Asset Mgmt (Nb Ca) holds 1.37% or 36,779 shares.
More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Nasdaq.com which released: “Should Intel’s (INTC) GPU Ambitions Bother NVIDIA & AMD? – Nasdaq” on April 02, 2019, also Nasdaq.com with their article: “Intel (INTC) Outpaces Stock Market Gains: What You Should Know – Nasdaq” published on April 01, 2019, Seekingalpha.com published: “Intel unveils Cascade Lake processors – Seeking Alpha” on April 02, 2019. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Seekingalpha.com and their article: “Nomura new Buy on Intel’s EPS potential – Seeking Alpha” published on April 03, 2019 as well as Nasdaq.com‘s news article titled: “Intel (INTC) Dips More Than Broader Markets: What You Should Know – Nasdaq” with publication date: March 08, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.